Saixing Group completed the acquisition of sterile injectable business unit from Lisapharma.

Saixing Group, a global investor based in China that operates primarily in the medical device and healthcare services sectors, completed the acquisition of the sterile injectable business unit, from Lisapharma, an Italian pharmaceutical company specialising in the production of sterile injectable medicines. Financial terms were not disclosed. The operation represents a crucial moment in the resolution of Lisapharma's crisis and lays the foundation for a relaunch of the company under the guidance of a leading international investor, active in medical devices and healthcare services. The Saixing Group's involvement enhances the technical skills present at the company and promotes new investments, with the aim of strengthening Lisapharma's position in the global markets for sterile injectable medicines.